What it is
PNC-27 is a laboratory peptide built from a piece of p53, the best-known tumour-suppressor protein. It joins two segments: the stretch of p53 from residue 12 to residue 26, which is the part p53 uses to dock onto a protein called HDM-2 (the human version of MDM-2), and a transmembrane-penetrating domain that carries the peptide into and across cell membranes (Sarafraz-Yazdi 2010, PNAS, PMID 20080680). PubChem lists it as C188H293N53O44S, molecular weight 4,032 (CID 16201774).
HDM-2 normally lives inside the cell, where it switches p53 off. The PNC-27 idea runs the other way: the developers report that many cancer cells also carry HDM-2 in their outer membrane, where normal cells do not, and use the p53 fragment as a homing device for it.
The peptide comes from one research group, at SUNY Downstate Medical Center in Brooklyn, whose first structural paper on the p53 fragment appeared in 2004 (Rosal 2004, Biochemistry, PMID 14967026). Most of the later literature carries the same senior authors.
How it is said to work
| Step | What the papers report | Source |
|---|---|---|
| Shape | The p53 residues inside PNC-27 take the same 3D shape as p53 does when bound to HDM-2 | Sarafraz-Yazdi 2010 |
| Target | HDM-2 found in the membranes of several cancer cell lines, not in untransformed lines | Sarafraz-Yazdi 2010 |
| Test of the target | Normal breast cells resistant to PNC-27 became susceptible once full-length HDM-2 was placed on their surface | Sarafraz-Yazdi 2010 |
| Result | Pores in the membrane, then rupture (necrosis), not programmed cell death | Bowne 2008 on PNC-28 (PMID 18931881); Sookraj 2010 (PMID 20182728) |
The group has named the mechanism "poptosis" — peptide-induced transmembrane pore formation — in a 2024 review led by Pincus, senior author of the 2010 paper (Biomedicines, PMID 38927351). The term is theirs; it is not a recognised category of cell death outside this literature.
What the evidence shows
All of it is pre-clinical. PubMed holds 23 records that match "PNC-27"; two of them are unrelated studies (child mortality in Nigeria, air pollution in Rome) that simply contain the string, which leaves about 21 on the peptide. None is a human trial.
| Kind of study | Examples | Human? |
|---|---|---|
| Cancer cell lines | ovarian, cervical, colon and leukaemia lines, plus breast lines in the 2010 paper (2010–2025, mostly in Ann Clin Lab Sci) | No |
| Patient tumour tissue in the dish | ovarian cancer cells taken from patients (Sarafraz-Yazdi 2015, PMID 26663795) | Tissue only |
| Mice | acute myeloid leukaemia transplant models, human and mouse (Wang 2020, Leukemia, PMID 31337857) | No |
| People | none found | — |
The 2020 Leukemia paper, from City of Hope in California rather than the Brooklyn group, is the strongest single result. PNC-27 killed both bulk leukaemia cells and the leukaemia stem cells that drive relapse, in primary and secondary transplant experiments, while normal blood-forming stem cells in wild-type mice kept their activity. Its conflict-of-interest statement records that Oncolyze, Inc. provided the PNC-27 used.
What is not established: whether membrane HDM-2 is present on human tumours inside the body at the levels seen in cell lines; what dose reaches a tumour; how long the peptide survives in human blood; and whether the sparing of normal cells holds in a person. No paper reports any of these in humans.
Where it stands
PNC-27 is not approved anywhere found. Drugs@FDA holds no application for it, and ClinicalTrials.gov listed no registered study on 2026-11-18. Any material labelled PNC-27 outside a research laboratory has had its identity, purity and sterility checked by no regulator.
Other peptides in the library that act on membranes include melittin from bee venom and the human antimicrobial peptide LL-37. FOXO4-DRI is another research peptide with a mouse-only record that sells far ahead of its evidence.
Sources opened 2026-11-18: Sarafraz-Yazdi 2010, PNAS (PMID 20080680, abstract); Wang 2020, Leukemia (PMID 31337857, abstract and conflict statement); PubMed E-utilities record list for "PNC-27" (23 records, titles read), including Rosal 2004 (PMID 14967026), Bowne 2008 (PMID 18931881), Sookraj 2010 (PMID 20182728), Sarafraz-Yazdi 2015 (PMID 26663795) and Pincus 2024 (PMID 38927351) by title; PubChem CID 16201774; ClinicalTrials.gov API v2; openFDA Drugs@FDA.
